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Abstract
Background: Urinary tract infections (UTI) are among the most frequent bacterial infections in older adults. The aim
of the study was to analyse the existence of differences in clinical features, microbiological data and risk of infection
by multidrug-resistant organisms (MDRO) between older and non-older men with febrile UTI (FUTI).
Methods: This was an ambispective observational study involving older males with a FUTI attended in the Emergency
Department. Variables collected included age, comorbidity, diagnostic of healthcare-associated (HCA)-FUTI, clinical
manifestations, hospitalization, mortality, and microbiological data.
Results: Five hundred fifty-two males with a FUTI, 329 (59.6%) of whom were older adults, were included. Older males had
a higher frequency of HCA-FUTI (p< 0.001), increased Charlson scores (p< 0.001), had received previous antimicrobial
treatment more frequently (p< 0.001) and had less lower urinary tract symptoms (p< 0.001). Older patients showed a
lower frequency of FUTI caused by E. coli (p< 0.001) and a higher rate of those due to Enterobacter spp. (p= 0.003) and P.
aeruginosa (p= 0.033). Resistance rates to cefuroxime (p= 0.038), gentamicin (p= 0.043), and fluoroquinolones (p< 0.001)
in E. coli isolates and the prevalence of extended-spectrum beta-lactamase and AmpC producing E. coli and Klebsiella spp.
strains (p= 0.041) and MDRO (p< 0.001) were increased in older males. Inadequate empirical antimicrobial treatment
(p= 0.004), frequency of hospitalization (p< 0.001), and all cause in-hospital mortality (p= 0.007) were higher among older
patients. In the multivariate analysis, being admitted from an long term care facility (OR 2.4; 95% CI: 1.06–5.9), having a
urinary tract abnormality (OR 2.2; 95% CI: 1.2–3.8) and previous antimicrobial treatment (OR 3.2; 95% CI: 1.9–5.4) were
associated to FUTI caused by MDRO.
Conclusions: Older male adults with a FUTI have different clinical characteristics, present specific microbiological features,
and antimicrobial resistance rates. In the multivariate analysis being an older male was not associated with an increased risk
of FUTI caused by MDRO.
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Background
The number of older adults is increasing in virtually
every country and will continue to grow over the coming
decades. According to the 2018 Ageing Report, by 2050
older adults will represent 28% of the European Union
citizens with an old-age dependency ratio of 55% of the
working-age population [1]. With an ageing and highly
dependent society the burden of infectious diseases is
expected to increase mainly due to a high prevalence of
older people with comorbid conditions, long-term
institutionalization, frailty and a weakened immune sys-
tem [2]. Infections in the older adults have specific char-
acteristics that have to be recognised in order to provide
an optimal care such as uncommon clinical presenta-
tions, high rates of organ failure and antimicrobial inter-
actions together with an increased severity and risk of
infections caused by multidrug-resistant organisms
(MDRO) [2].
Urinary tract infections (UTI) are one of the most
common bacterial infections affecting geriatric patients
and the main source of community acquired bacteremia
[3, 4]. After pneumonia, UTI represent the second cause
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of hospital admission due to an infection in the older
adults [5]. Despite their high frequency, UTI are fre-
quently overdiagnosed due to the high prevalence of
asymptomatic bacteriuria (ASB) in older populations
which may lead to an incorrect diagnostic and unneces-
sary antimicrobial treatment in the presence of non-
specific urinary symptoms [3, 6]. This increased expos-
ure to antimicrobials is one of the main factors explain-
ing the high prevalence of UTI due to MDRO in the
older adults including those caused by extended-
spectrum betalactamase (ESBL) producing Enterobacte-
riaceae [7, 8].
Women are more prone to experience UTI although
rates tend to equalise in ageing males due to impaired
normal voiding mainly associated with benign prostatic
hyperplasia (BPH) [9]. The main consequence of these
voiding difficulties is the generation of a retrograde turbu-
lent urine flow, enabling the ascension of uropathogens to
the bladder and eventually into the prostate, which ex-
plains the high frequency of prostatic involvement in
males with UTI [10]. Therefore, most febrile UTI (FUTI)
in males should be considered as acute bacterial prostatitis
(ABP) and treated using antimicrobials with an adequate
prostatic diffusion such as fluoroquinolones (FQ) [11]. In-
creasing antimicrobial resistance rates hinder the eradica-
tion of the bacteria from the prostate thus becoming the
source of recurrent UTI in males [3].
The majority of the studies that have analysed the
characteristics of FUTI in older populations have fo-
cused on women [12, 13]. Therefore, we believe there is
a knowledge gap regarding the characteristics of FUTI in
older males. The objective of this study was to investi-
gate the existence of differences in clinical features,
microbiological data and risk of infection by MDRO be-
tween older and non-older men with FUTI.
Methods
Study design
This was an ambispective observational study in which we
evaluated males aged > 18 years with a FUTI and a positive
urine culture seen at the emergency department (ED) of a
165-bed primary care hospital from 2008 to 2015. Informa-
tion was recorded retrospectively until 2009 and prospect-
ively thereafter. FUTI was defined as an axillary
temperature > 38 °C, measured at home or the ED, and one
or more lower urinary tract symptoms (LUTS) including
urinary urgency, frequency and/or dysuria. In the absence
of LUTS the patient was diagnosed as having a FUTI when
no additional focus of infection was identified. FUTI epi-
sodes with negative or polymicrobial urine cultures were
excluded from the analysis. The study was approved by the
Clinical Research Ethics Committee of the “La Fundació
Unió Catalana d’Hospitals” (approval number: CEIC 16/
58). Written informed consent was obtained from patients
prospectively included.
Study population, description of measures and definitions
Patients were divided into older and non-older males.
Male patients aged 65 years or above were identified as
older patients. Males aged between 65 and 79 were con-
sidered early older patients while those aged 80 years or
above were considered to be late older patients. Men
under 65 were defined as non-older. The variables col-
lected from each patient included age, dementia,
healthcare-associated (HCA)-FUTI, diabetes mellitus,
kidney failure, cirrhosis, neoplastic disease, chronic ob-
structive lung disease, heart failure, use of immunosup-
pressives in the previous 30 days, comorbidity Charlson
age adjusted score [14], antibiotic treatment in the prior
30 days, existence of urinary tract abnormalities or past
UTI episodes. We also recorded information regarding
the patients symptoms and from their physical examin-
ation at the ED including the axillary temperature and
the mean arterial pressure (MAP). Patients were tracked
until hospital discharge or death. In case of recurrent
FUTI, only the initial episode was analysed.
We considered that the patient had a HCA-FUTI in
case of: hospitalization for 2 or more days in the previ-
ous 90 days; residence in an long-term care facility
(LTCF); intravenous therapy at home or in a day hos-
pital, hemodialysis, specialized nursing care, invasive
urinary tract instrumentation, 30 days before the FUTI;
presence of an indwelling urethral catheter (IUC) in
place or removed 48 h before the infection including
short term (< 30 days) and long term (> 30 days) cathe-
ters. Patients without any of the prior criteria were cata-
logued as having a community-acquired FUTI.
Urine specimens were collected from clean-catch mid-
stream urine. In case of long-term IUC it was recom-
mended to obtain urine samples from a newly inserted
catheter. Samples were cultured on CLED and MacConkey
agar and considered positive in case of bacterial growth >
103 colony-forming units/mL. Standard biochemical
methods were used for microbiological identification. Anti-
microbial susceptibility of the isolated bacteria was per-
formed by the disk diffusion technique according to the
recommendations of the Clinical and Laboratory Standards
Institute. The antibiotics tested included: amoxicillin,
amoxicillin-clavulanate acid, cefuroxime, ceftriaxone, imi-
penem, gentamicin, nalidixic acid, ciprofloxacin, co-
trimoxazole, and fosfomycin. Resistant and intermediate
strains were pooled together for statistical analysis. The iso-
lates were screened for ESBLs and Amp-C β-lactamases
production by phenotypic methods. Microorganisms were
considered as MDRO in case of expressing an acquired re-
sistance to at least one agent in three or more antimicrobial
categories [15].
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The 2001 definitions were used to define severe sepsis
and septic shock [16]. Inadequate empirical antimicro-
bial treatment (IEAT) was defined in case the isolated
uropathogen was resistant to the first antibiotic adminis-
tered at the ED or when treating with a third-generation
cephalosporin (TGC) in monotherapy FUTI due to mi-
croorganisms with inducible chromosomal beta-
lactamases (mainly Enterobacter spp., Serratia spp., C.
freundii, M. morgagnii and Providencia spp). All-cause
in-hospital mortality was defined when the patient died
during the hospitalization independently of its causes
while FUTI-related in-hospital mortality when the pa-
tient died due to the infection.
Statistical analysis
Dichotomous variables are presented as number of pa-
tients (percentages) and continuous variables as mean (+
standard deviations). Dichotomous variables were com-
pared by using the Chi-square or the Fisher exact test as
appropriate while continuous variables were compared
by the Student t-test or the Mann-Whitney U-test. A lo-
gistic regression analysis was performed to identify inde-
pendent variables associated with infections caused by
MDRO. Variables with a p < 0.1 in the univariate ana-
lysis were included in the multivariate analysis. Model
validity was evaluated by the Hosmer-Lemeshow test for
estimating goodness of fit. Statistical significance was de-
fined as a two-tailed P value of < 0.05. Data were ana-
lyzed with SPSS 20.0.
Results
Five hundred and fifty-two males with a FUTI attended
in the ED were included in the study. Three hundred
and twenty-nine (59.6%) were older and 223 (40.4%)
non-older patients. Among the older males, 210
(63.8%) were classified as early older and 119 (36.2%) as
late older patients. Overall, 356 patients (64.5%) had
one or more chronic medical conditions. Of the in-
cluded patients, 239 (43.4%) had a previous diagnosis of
BPH which represented the most common urinary tract
abnormality. The baseline characteristics, clinical fea-
tures, empirical treatment and outcomes of the patients
are shown in Table 1. Older males had an increased fre-
quency of HCA-FUTI, and the vast majority of the
medical conditions analysed and thus had higher Charl-
son scores. Previous UTI episodes, the existence of
urinary tract abnormalities, and antimicrobial intake in
the preceding month, mainly with FQ, were also more
common in older patients. In addition, older males
more frequently had an IUC half of which were long-
term catheters and the rest short-term catheters mainly
placed after urological surgery. None of the patients
were on hemodialysis.
Regarding the clinical presentation, older males pre-
sented less LUTS, flank pain and lumbar tenderness with
a similar degree of fever than non-older males. The
MAP was lower in the older patients although no differ-
ences in the frequency of severe sepsis and septic shock
were found when compared to non-older patients. Be-
sides, older males presented an increased frequency of
bacteremic FUTI.
The isolated uropathogens and their antimicrobial re-
sistant pattern is shown in Table 2. E. coli was the pre-
dominant pathogen in older and non-older patients
followed by K. pneumonia and P. aeruginosa. E. coli was
less commonly isolated in older males, although it was
still the most common causal uropathogen. Resistance
rates to cefuroxime, gentamicin, and FQ were higher in
E. coli strains isolated from older patients. When evalu-
ated together, ESBL and AmpC producing E. coli and
Klebsiella spp. were more prevalent among older pa-
tients. No carbapenemase-producing Enterobacteriaceae
strains were isolated during the study period. The fre-
quency of Enterobacter spp. and P. aeruginosa was also
higher in older males. Patients with long-term IUC had
a lower frequency of FUTI caused by E. coli (35% vs
74%; p < 0.001), and an increased risk of those caused
by K. pneumoniae (22.5% vs 7.4%; p 0.004), P. aeruginosa
(17.5% vs 3.5%; p 0.001), and P. mirabilis (10% vs 2.5%;
p 0.028) together with higher rates of infections caused
by MDRO (Table 3) when compared to patients with
short-term IUC.
As shown in Table 3 the frequency of infections
caused by MDRO was higher in older patients. In the
multivariate analysis independent risk factors for having
a FUTI caused by a MDRO were coming from an LTCF,
having a urinary tract abnormality and recent antimicro-
bial treatment but not with being an older male patient.
Regarding empirical antimicrobial treatment, TGC was
the main therapeutic option used in older and non-older
patients. A higher number of older males received em-
pirical treatment with either a carbapenem or with
piperacillin-tazobactam (Table 1). Older patients more
frequently received an IEAT and were treated with
OPAT, mainly with ertapenem in 25 (46.3%) cases and
with ceftriaxone in 23 (42.6%) patients. Older males also
required hospital admission more often with longer
length of hospitalization and exhibited an increased
crude and attributable in-hospital mortality compared
with non-older patients (Table 1). A multivariate ana-
lysis of risk factors associated to in-hospital mortality
was not performed due to the small number of deaths
among the included patients.
Discussion
According to our study, older males with a FUTI present
specific clinical characteristics, different microbiological
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Table 1 Basal characteristic, clinical features, empirical antimicrobial treatment and outcomes of included patients and analysis of
existing differences between older and non-older patients with a febrile urinary tract infection
Characteristicsa All patients (n = 552) Older (n = 329) Non-older (n = 223) P value
Baseline conditions
Age (years) 66.1 + 16.7 77.3 + 7.6 49.5 + 12.2 < 0.001
HCA-FUTI 203 (36.8) 177 (53.8) 26 (11.7)s < 0.001
Previous hospital admission 130 (23.6) 114 (34.7) 16 (7.2) < 0.001
Long term care facility 46 (8.3) 43 (13.1) 3 (1.3) < 0.001
IV home-day hospital treatment 13 (2.4) 9 (2.7) 4 (1.8) 0.47
Specialized nursing care 7 (1.3) 6 (1.8) 1 (0.4) 0.25
Indwelling urinary catheter 76 (13.8) 66 (20.1) 10 (4.5) < 0.001
Long-term IUC 40 (7.2) 33 (10) 7 (3.1) 0.002
Short- term IUC 36 (6.5) 33 (10) 3 (1.3) < 0.001
Invasive urinary intrumentation 110 (19.9) 98 (29.8) 12 (5.4) < 0.001
Dementia 64 (11.6) 62 (18.8) 2 (0.9) < 0.001
Diabetes mellitus 148 (26.8) 113 (34.3) 35 (15.7) < 0.001
Chronic kidney failure 54 (9.8) 49 (14.9) 5 (2.2) < 0.001
Cirrhosis 9 (1.6) 5 (1.5) 4 (1.8) 1
Neoplasia 81 (14.7) 72 (21.9) 9 (4) < 0.001
Heart failure 8 (1.4) 7 (2.1) 1 (0.4) 0.15
Chronic obstructive lung disease 100 (18.1) 90 (27.4) 10 (4.5) < 0.01
Immunosuppressive or corticosteroid treatment 11 (2) 7 (2.1) 4 (1.8) 1
Charlson score 3.6 + 2.5 5.1 + 1.7 1.3 + 1.6 < 0.001
Previous UTI 222 (45.5) 152 (53.7) 70 (34.1) < 0.001
Urinary tract abnormality 339 (61.5) 252 (76.8) 87 (39) < 0.001
BPH 239 (43.4) 187 (57) 52 (23.3) < 0.001
Urogenital cancer 48 (8.8) 44 (13.6) 4 (1.8) < 0.001
Previous antibiotic treatment 179 (32.6) 135 (41.3) 44 (19.8) < 0.001
Aminopenicillins 60 (11) 42 (13) 18 (8.2) 0.081
Fluoroquinolones 54 (9.9) 41 (12.7) 13 (5.9) 0.010
TGC 16 (2.9) 11 (3.4) 5 (2.3) 0.44
Fosfomycine 10 (1.8) 9 (2.8) 1 (0.5) 0.055
Clinical presentation
LUTS 359 (65.3) 172 (52.4) 187 (84.2) < 0.001
Flank pain 89 (16.2) 31 (9.5) 58 (26.1) < 0.001
Physical examination
Temperature 37.7 + 1 37.7 + 1.1 37.7 + 0.9 0.85
MAP (mmHg) 93.4 + 15.3 91.1 + 15.3 96.9 + 14.7 < 0.001
Lumbar tenderness 94 (22.1) 40 (17.3) 54 (27.7) 0.010
Prostatic tenderness 81 (42.6) 35 (37.2) 46 (47.9) 0.13
Laboratory
WBC count (leukocytes/mm3) 13,903 + 5743 13,348 + 5536 14,759 + 5961 0.006
Creatinine (mg/dl) 1.2 + 0.7 1.4 + 0.8 1.1 + 0.4 < 0.010
Bacteremia 120 (31.6) 92 (38) 28 (20.3) < 0.010
Treatment
Empirical treatment with TGC 307 (55.6) 176 (53.5) 131 (58.7) 0.22
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and antimicrobial-resistant patterns and outcomes when
compared to non-older males. Due to the high frequency
of UTI among older patients it is important to consider
these differences when attending geriatric males with
FUTI in the ED in order to provide an optimal thera-
peutic care.
Normal voiding is the most important defense against
UTI. Increased postvoid residual volume, which occurs
in ageing males mainly related to BPH, causes urinary
stasis and predisposes to UTI. Urinary tract abnormal-
ities and IUC are additional contributors to UTI in geri-
atric patients [3, 17, 18]. As expected, a higher frequency
of urinary tract abnormalities, mainly BPH but also uro-
genital cancer, was observed in older patients. In a study
by Søgaard et al., acute pyelonephritis in patients older
than 50 years was identified as a marker of urogenital
cancer suggesting that older patients with FUTI should
be evaluated to rule out this possibility [19].
Regarding the clinical presentation, more than half of
the included older males presented LUTS, in accordance
to what has been previously described [3]. Despite the
frequent existence of urinary symptoms in older males,
we observed a lower frequency of LUTS, flank pain and
lumbar tenderness compared to non-older patients. A
lower frequency of localizing urinary symptoms in older
patients with a FUTI has been observed in previous
studies, particularly in those living in LTCF [3, 12, 20].
Although fever is frequently absent or blunted in geriat-
ric patients with an acute infection, no differences in the
degree of fever were seen between older and non-older
patients [21]. Fever without localizing genitourinary
signs and symptoms is the most common presentation
of symptomatic UTI in residents from an LTCF with an
IUC [3]. As pyuria and bacteriuria are practically con-
stant in patients with a long-term IUC when fever is
present an alternative focus of infection has to be ruled
out before being attributed to a urinary infection [18].
The evaluation of UTI in geriatric patients can be chal-
lenging due to defective communication, functional disabil-
ity and the existence of chronic LUTS usually not
attributable to UTI [3, 18]. Although non-specific changes
in the clinical status of older patients such as delirium, in-
creased falls, fatigue or loss of appetite, are frequently at-
tributed to UTI, particularly in the presence of a positive
urine culture, the value of these symptoms as indicators of
a proper UTI has been questioned [3, 6, 22, 23]. According
to a recent decision tool for deciding empiric antimicrobial
treatment in frail older adults with suspected UTI and the
2019 IDSA guidelines for the management of ASB, most
non-specific symptoms in the absence of LUTS or other
signs of infection should not be attributed to UTI [24, 25].
Therefore, due to the high prevalence of pyuria and ASB in
older patients, urinalysis should only be performed when
signs and symptoms of UTI are present [3, 18, 24].
In our study, FUTI in older males were less commonly
caused by E. coli with an increased frequency of infections
due to other gram-negative bacteria, which is in accord-
ance with previous studies [2]. E. coli isolated from older
males exhibited increased resistance rates to cefuroxime,
gentamicin, and FQ. We also observed a higher prevalence
of ESBL and AmpC producing E. coli and Klebsiella spp.
strains with rates similar to the ones reported by Alvarez
et al. among older patients with UTI [26]. The impact of
age in the frequency of FUTI caused by MDRO has been
observed in some studies [8, 12] but not in others [27, 28].
Interestingly, men seem to have an increased risk of infec-
tion with ESBL-producing Enterobacteria and other
MDRO compared to women [8, 28, 29].
In the multivariate analysis, coming from an LTCF, hav-
ing a urinary tract abnormality and recent antimicrobial
Table 1 Basal characteristic, clinical features, empirical antimicrobial treatment and outcomes of included patients and analysis of
existing differences between older and non-older patients with a febrile urinary tract infection (Continued)
Characteristicsa All patients (n = 552) Older (n = 329) Non-older (n = 223) P value
Empirical treatment with carbapenems or PT 59 (10.7) 46 (14) 13 (5.8) 0.002
IEAT 95 (17.2) 69 (21) 26 (11.7) 0.004
OPAT 71 (12.9) 54 (16.4) 17 (7.6) 0.002
Outcomes
Severe sepsis or septic shock 17 (3.1) 12 (3.6) 5 (2.2) 0.35
Hospital admission 266 (48.2) 197 (59.9) 69 (30.9) < 0.001
Length of hospitalisation (days) 2.6 + 4.1 3.3 + 4.6 1.4 + 2.9 < 0.001
Length antimicrobial therapy (days) 16.3 + 6.7 16 + 7 16.8 + 6.5 0.19
All-cause in-hospital mortality 15 (2.7) 14 (4.3) 1 (0.4) 0.007
Attributable in-hospital mortality 8 (1.4) 8 (2.4) 0 0.024
Abbreviations: BPH Benign prostatic hyperplasia, HCA-FUTI Healthcare-associated febrile urinary tract infection, IEAT Inadequate empirical antimicrobial treatment,
IUC Indwelling urinary catheter, LUTS Lower urinary tract symptoms, MAP Mean arterial pressure, OPAT Outpatient parenteral antimicrobial therapy, PT Piperacillin-
tazobactam, TGC Third-generation cephalosporins, UTI Urinary tract infections, WBC White blood cell
aData presented as mean + standard deviation (SD) or numbers of patients (percentages)
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use were independently associated to FUTI caused by
MDRO. Residing in an LTCF has been identified as a risk
factor for infection caused by ESBL-producing Enterobac-
teria [8, 28, 29]. Pulcini et al. showed that older people
from nursing homes had a 40% risk of having an
antibiotic-resistant Enterobacteriaceae isolated from the
urine compared to their community peers [30]. More re-
cently, McKinnell et al. estimated a prevalence of MDRO
colonization in older people from nursing homes and
long-term acute care facilities of 65 and 80% respectively
[31]. All these studies support the role of LTCF as reser-
voirs of MDRO.
Recent exposure to antimicrobials, as in previous stud-
ies, was also associated with FUTI due to MDRO [8, 28].
Antimicrobial consumption is particularly high among
residents of LTCF. It has been estimated that 75% of the
residents of LTCF who stay for 6 months or longer will
receive at least one course of antibiotics, commonly for
suspected UTI in older patients with pyuria or ASB and
non-specific urinary symptoms [18]. Given the burden
of inappropriate management of ASB, particularly in
LTCF, it is crucial to establish antimicrobial stewardship
programs that have demonstrated to decrease antimicro-
bial consumption [32].
In an attempt to decrease antimicrobial overtreatment
it has been recommended to avoid therapy in older pa-
tients with ASB and non-specific urinary symptoms or
even to defer it in case of mild urinary symptoms await-
ing urine culture results [3]. These recommendations
have been questioned in an article by Gharbi et al. in
which the authors suggest that not prescribing or defer-
ring antimicrobials in older patients with a UTI
Table 2 Isolated uropathogens and antimicrobial resistance profiles
Uropathogensa All patients (n = 552) Older (n = 329) Non-Older (n = 223) P value
Escherichia coli 393 (71.2) 206 (62.6) 187(83.9) < 0.001
Amoxicillin 254 (69.2) 137 (71.4) 117 (67) 0.35
Amoxicillin-clavulanate 52 (13.3) 33 (16.2) 19 (10.2) 0.080
Cefuroxime sodium 38 (9.7) 26 (12.6) 12 (6.4) 0.038
Ceftriaxoneb 35 (8.9) 23 (11.2) 12 (6.4) 0.099
Gentamicin 30 (7.7) 21 (10.2) 9 (4.8) 0.043
Fluoroquinolones 153 (38.9) 100 (48.5) 53 (28.3) < 0.001
Co-trimoxazol 102 (26.8) 56 (28.3) 46 (25.3) 0.51
Fosfomycine 8 (2.1) 6 (3.1) 2 (1.1) 0.28
Klebsiella spp.c 56 (10.1) 40 (12.2) 16 (7.2) 0.057
Amoxicilline-clavulanate 13 (23.2) 8 (20) 5 (31.3) 0.48
Ceftriaxoned 12 (21.4) 9 (22.5) 3 (18.8) 1
Fluoroquinolones 15 (26.8) 12 (30) 3 (18.8) 0.51
Co-trimoxazol 11 (20.8) 8 (21.1) 3 (20) 1
ESBL and AmpC producing E. coli and Klebsiella spp. 48 (10.7) 33 (13.4) 15 (7.4) 0.041
Enterobacter spp.e 21 (3.8) 19 (5.8) 2 (0.9) 0.003
Serratia spp. 4 (0.7) 3 (0.9) 1 (0.4) 0.65
Citrobacter spp. 4 (0.7) 1 (0.3) 3 (1.3) 0.3
Morganella spp. 5 (0.9) 4 (1.2) 1 (0.4) 0.65
Proteus mirabilis 17 (3.1) 14 (4.3) 3 (1.3) 0.052
Pseudomona aeruginosa 25 (4.5) 20 (6.1) 5 (2.2) 0.033
Fluoroquinolones 7 (28) 7 (35) 0 0.27
Other Gram negative bacteriaf 2 (0.4) 2 (0.6) 0 0.51
Gram positive bacteria 22 (4) 17 (5.2) 5 (2.2) 0.085
Enterococcus spp.g 16 (2.9) 12 (3.6) 4 (1.8) 0.20
Staphylococcus spp. h 6 (1.1) 5 (1.5) 1 (0.4) 0.41
Candida spp.i 3 (0.5) 3 (0.9) 0 0.27
Abbreviations: ESBL extended-spectrum beta-lactamase
aData presented as number of patients (percentages). bInclude 32 (91.4%) ESBL and 3 (8.6%) AmpC producing strains. cInclude 47 (84%) K. pneumoniae and 9
(16%) K. oxytoca strains. dInclude 9 (75%) ESBL and 3 (25%) AmpC producing strains. eInclude 18 (85.7%) E. cloacae and 3 (14.3%) de E. aerogenes strains. fInclude
one P. stuartii strain and one A. baumannii strain. gInclude 11 (68.7%) E. faecalis, 4 (25%) Enterococcus spp. and 1 (6.3%) E. faecium strains. hInclude 6 (83.3%) S.
aureus and 1 (16.7%) S. capitis strain. iInclude 2 C. albicans and 1 C. tropicalis strains
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increases the risk of bloodstream infection, hospital ad-
mission and all-cause mortality [33].
Older males with underlying urinary tract abnormal-
ities also had an increased risk of infection by MDRO.
Although having urinary abnormalities has been consid-
ered a risk factor for having UTI caused by resistant uro-
pathogens [34] different studies show conflicting results.
While Lee et al. observed a relationship between
bacteremic UTI caused by MDRO and different urinary
tract abnormalities [35], in a study by Gomila et al. only
the presence of an IUC was associated with UTI caused
by MDRO in hospitalised patients [28].
Once a FUTI is diagnosed, an empirical antimicrobial
treatment has to be started to avoid progression to sepsis
or even septic shock. In our study, older males received
more frequently a carbapenem or piperacillin-tazobactam
than non-older male. The decision to indicate a broad
spectrum antibiotic should be based on the severity of the
infection, the presence of known risk factors for MDRO
and the local antimicrobial resistance rates. An increase in
the consumption of carbapenems has been identified as a
driver for carbapenemase resistance among Enterobacteria-
ceae strains [36]. In the present study, 21% of the older
males received an IAET, which was lower than the fre-
quency described in previous studies in older patients
with UTI with rates that ranged from 27.4 to 29.3%
[26, 37, 38].
Regarding directed antimicrobial therapy, as prostatic
involvement in males with FUTI is common, FQ have
been considered the first therapeutic choice due to their
high degree of prostatic penetration [11]. The use of FQ
is limited due to high resistant rates and the risk of se-
vere adverse events related to its use, including aortic
aneurysms [39]. Co-trimoxazol is an alternative but
again high resistance rates and the risk of acute kidney
injury and hyperkalemia in older adults hampers its use
[40]. Fosfomycine has emerged as an additional option
for directed therapy as it achieves reasonable intrapro-
static concentrations and it is active against most MDRO
including ESBL strains [41]. Regarding the duration of
antimicrobial treatment in males with FUTI, very few
studies have analysed this topic. Ulleryd et al. showed
that 14 day was not inferior to 28 day treatment while
more recently van Niewkoop et al. demonstrated that 7
days was less efective than 14 day treatment in males
with FUTI [42, 43]. In our study, older and non-older
patients received slightly more than 2 weeks of anti-
microbial therapy.
Management of IUC in FUTI is also important, particu-
larly in older patients who are frequently catheterized.
Table 3 Univariate and multivariate analysis of risk factors associated with febrile urinary tract infection caused by multidrug-
resistant organisms
Characteristicsa MDRO infection (n = 135) Non-MDRO infection (n = 414) P value2 OR (95% CI) P value3
Older males 98 (72.6) 228 (55.1) < 0.001
Previous hospital admission 46 (34.1) 81 (19.6) 0.001
Long term care facility 23 (17) 22 (5.3) < 0.001 2.4 (1.06–5.9) 0.037
IV home-day hospital treatment 1 (0.7) 12 (2.9) 0.2
Specialized nursing care 2 (1.5) 5 (1.2) 0.68
Indwelling urethral catheter 29 (21.5) 46 (11.1) 0.002
Long-term IUC 21 (15.6) 19 (4.6) < 0.001
Short-term IUC 8 (5.9) 27 (6.5) 0.8
Invasive urinary Instrumentation 38 (28.1) 69 (16.7) 0.003
Dementia 27 (20) 36 (8.7) < 0.001
Diabetes mellitus 40 (29.6) 106 (25.6) 0.36
Chronic kidney failure 16 (11.9) 37 (8.9) 0.32
Cirrhosis 2 (1.5) 7 (1.7) 1
Neoplasia 22 (16.3) 57 (13.8) 0.46
Heart failure 4 (3) 4 (1) 0.1
Chronic obstructive lung disease 30 (22.2) 70 (16.9) 0.16
Immunosuppressive or corticosteroid treatment 1 (0.7) 10 (2.4) 0.31
Previous UTI 74 (62.2) 148 (40.1) < 0.001
Urinary tract abnormality 100 (74.6) 236 (57) < 0.001 2.2 (1.2–3.8) 0.006
Previous antibiotic treatment 71 (53) 107 (26) < 0.001 3.2 (1.9–5.4) < 0.001
Abbreviations: CI Confidence interval, IUC Indwelling urinary catheter, MDRO Multidrug-resistant organisms, OR Odds ratio, UTI Urinary tract infections
aData presented as numbers of patients (percentages).2Univariate analysis.3Multivariate analysis
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IDSA guidelines recommend replacing a long-term IUC
to hasten the resolution of symptoms in catheter-
associated UTI [44]. This recommendation has recently
been questioned in a study by Babich et al. in which the
authors found no clinical benefit from replacing a long-
term IUC at the onset of a catheter-associated UTI [45].
In a later editorial letter, the authors were questioned
about the IDSA guidance to obtain a urine culture from a
freshly placed catheter as a sample from a long-term IUC
might not reflect the status of the infection in the bladder.
The authors replied that in 97% of cases of bacteremia the
same species was isolated from the urine while recogniz-
ing the need for further research with randomized con-
trolled trials [46].
As in previous studies, older patients required hospital
admission more frequently with longer length of
hospitalization [3, 12]. Also, older patients had an in-
hospital mortality rate of 4.3%, which was higher com-
pared to non-older patients but significantly lower than
the rates reported in previous studies in geriatric pa-
tients with UTI with rates that ranged from 8.9 to 33%
[26, 37, 47, 48]. Severe sepsis and septic shock are the
risk factors that most robustly have been associated with
increased mortality in patients with FUTI [26, 38, 47].
Despite several studies have found age to increase mortal-
ity in patients with sepsis [26, 38, 47], others point out that
preexisting medical conditions, including chronic kidney
failure, could play a more prominent role [49, 50].
The present study has some potential limitations that
have to be taken into consideration. Firstly, the study had
a retrospective component and was performed in a single
hospital. Secondly, we did not evaluate certain clinical data
that would have been worth analysing in older male pa-
tients with FUTI including the functional status, the pres-
ence of urinary incontinence, altered mental status or
delirium. Thirdly, we excluded from the analysis FUTI ep-
isodes with negative or polymicrobial urine culture which
might have induced a selection bias. Finally, the data col-
lection was limited to the hospitalization period which
might have underestimated the outcomes.
Conclusions
Despite these limitations, our study indicates that older
males with FUTI present different clinical characteristics
and show specific microbiological features and increased
antimicrobial resistance rates. In the multivariate ana-
lysis age was not associated with infections caused by
MDRO.
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